Sangamo Biosciences Receives ‘Buy’ Rating from Patrick Trucchio Amid Anticipated Collaborations and Gene Therapy Advances
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target ...